CSE:TRIP - Post Discussion
Post by
Betteryear2 on Feb 09, 2024 12:21pm
Red Light Holland and PharmAla to Collaborate
- PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light Holland
Toronto, Ontario--(Newsfile Corp. - February 9, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce it has entered into a consulting relationship with PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla"), to consult on the development of clinical-grade Psilocybin Drug Product extracted from Red Light Holland's naturally occurring psilocybin truffles.
Red Light Holland and PharmAla to Collaborate on Medical Psilocybin Development (newsfilecorp.com)
Be the first to comment on this post